• Home
  • Company
    • Management
    • Board of Directors
    • Advisory Board
  • Technology
    • Publications
  • Partnering
    • Product Pipeline
  • News
    • IN THE PRESS: Cloud Pharmaceuticals CSO Shahar Keinan in "The Scientist"
    • Cloud Pharmaceuticals to Present AI-Based Drug Design at Conferences in May
    • Cloud Pharmaceuticals Wins U.S.-China Health Summit
    • Cloud Pharmaceuticals Selected Finalist in U.S.-China Health Summit
    • Cloud Pharmaceuticals forms Drug Design Collaboration with GSK
    • Cloud Pharmaceuticals CEO to Speak at Artificial Intelligence in Drug Development Congress 27-28 September 2017, London, UK
    • Cloud Pharmaceuticals CEO and CSO to Speak at AI Pharma Innovation
    • Cloud Pharmaceuticals CEO to Speak at the AI in Pharma Summit October17, 2017 in Boston.
    • Cloud Pharmaceuticals CEO and CSO to Speak at AI Pharma Innovation
    • Undruggable? Not to Cloud Pharmaceuticals
    • Cloud Pharmaceuticals Announces Design of Active Pro-Drug for Treatment of Crohn's Disease and Ulcerative Colitis
    • Cloud Pharmaceuticals COO to Discuss Digital Tools for Drug Discovery and Development at the 2016 BIO International Convention
    • Cloud Pharmaceuticals Appoints Neurological Disorder Expert Jeff Vaught to Its Advisory Board
    • Cloud Pharmaceuticals Strengthens Management Team with Appointment of Two C-Level Executives
  • Events
  • Contact
Cloud Pharmaceuticals
Connect with us:

News

Follow @CloudPharm
Cloud Pharmaceuticals COO to Discuss Digital Tools for Drug Discovery and Development at the 2016 BIO International Convention

Don Van Dyke to join panelists to discuss harnessing the power of AI and computer modeling to design and develop medicines at lower cost and faster time to market

Research Triangle Park, NC (May 24, 2016) -- Don Van Dyke, COO of Cloud Pharmaceuticals Inc., a cloud-based drug design and development company, is being featured as a panelist at the 2016 BIO International Convention taking place June 6 through 9, 2016 in San Francisco, Calif. The session, titled “Digital Tools for Drug Discovery and Development: Leverage Moore’s Law to Improve Therapeutics,” is being held June 9, 2016, from 9:00 to 10:15 am in room West 3006. Van Dyke and fellow panelists will explore advances in computer modeling to reduce drug development cost and improve time to market.
 
“The computational design of drugs has faced stumbling blocks in the past but several things have come together to make it the most promising venue for drug discovery,” says Van Dyke. “Cloud computing combined with the continued influence of Moore's Law has provided an unprecedented opportunity to apply inexpensive high-performance computing to drug discovery. This combination offers new techniques that can be combined to achieve success at a higher level – from molecule design through clinical trials. It allows us to harness the power of artificial intelligence (AI) to design molecules that can heal and save.”

The application of cloud computing combined with AI technology enables computational chemistry processes and sophisticated molecular modeling to search virtual molecular space and design novel drugs that are well-qualified for development from the outset. This approach represents the digital disruption of drug design, enabling faster development at lower cost and a higher success rate with better targeting of hard-to-drug indications.

“The goal is to not only reduce cost and improve speed,” Van Dyke adds. “It’s about producing much-improved compounds that have a high probability of success at becoming safe, effective, and marketable drugs. This technology represents a tremendous step forward in computational drug design, with broad applications in drug discovery.”
About Cloud Pharmaceuticals, Inc.

Cloud Pharmaceuticals is committed to improving health and well-being through the computational design and rapid development of new therapies. Its proprietary Quantum Molecular Design process combines artificial intelligence (AI) and cloud computing to search virtual molecular space and applies along sophisticated molecular modeling to design novel drugs. The process enables faster drug development progress at lower cost and a higher success rate and better targeting of hard-to-drug indications. The company partners at all stages of drug development – from discovery through the clinic – and is building an extensive product pipeline that spans a wide range of indications.
###
HOME | COMPANY | TECHNOLOGY | PARTNERING | NEWS | EVENTS | CONTACT

CONTACT US:

Cloud Pharmaceuticals, Inc.

Office: 800 Park Offices Dr., RTP, NC 27709
Mail: PO Box 110081, RTP, NC 27709
Phone: 1.910.398.1200
e-mail: info@cloudpharmaceuticals.com
CONNECT WITH US:


SUBSCRIBE:

Join our contact list to receive news and announcements in your inbox:

Join Now
© 2014 - 2019 Cloud Pharmaceuticals, Inc. | Terms and Conditions of access to www.cloudpharmaceuticals.com